Similar articles

• Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy.

  Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, Wellbrock C. Smith MP, et al. Cancer Cell. 2016 Mar 14;29(3):270-284. doi: 10.1016/j.ccell.2016.02.003. Cancer Cell. 2016. PMID: 26977879 Free PMC article.
• Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.

  Pathria G, Garg B, Borgdorff V, Garg K, Wagner C, Superti-Furga G, Wagner SN. Pathria G, et al. Cell Death Dis. 2016 Mar 10;7(3):e2135. doi: 10.1038/cddis.2015.369. Cell Death Dis. 2016. PMID: 26962685 Free PMC article.
• TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF^V600E melanoma cells.

  Hartman ML, Czyz M. Hartman ML, et al. Arch Dermatol Res. 2020 Jul;312(5):385-392. doi: 10.1007/s00403-019-01995-w. Epub 2019 Oct 17. Arch Dermatol Res. 2020. PMID: 31624899 Free PMC article.
• Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.

  Holderfield M, Deuker MM, McCormick F, McMahon M. Holderfield M, et al. Nat Rev Cancer. 2014 Jul;14(7):455-67. doi: 10.1038/nrc3760. Nat Rev Cancer. 2014. PMID: 24957944 Free PMC article. Review.
• Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.

  Carlino MS, Long GV, Kefford RF, Rizos H. Carlino MS, et al. Crit Rev Oncol Hematol. 2015 Dec;96(3):385-98. doi: 10.1016/j.critrevonc.2015.08.021. Epub 2015 Aug 28. Crit Rev Oncol Hematol. 2015. PMID: 26358420 Review.